LIVN LivaNova PLC
Electromedical & Electrotherapeutic Apparatus · Nasdaq · SEC CIK 1639691 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY11.7%
TTM net income YoY190.1%
TTM EPS YoY187.7%
Revenue 3-yr CAGR10.5%
Net income 3-yr CAGR308.9%
Margins
Gross margin67.8%
Operating margin10.7%
Net margin13.0%
FCF margin8.6%
EBITDA margin13.0%
Returns
ROE15.5%
ROA7.4%
ROIC (approx.)15.8%
Asset turnover0.57x
Leverage & solvency
Liabilities / assets49.4%
Debt / equity0.22x
Current ratio1.46x
Interest coverage4.73x
Cash quality & payout
Operating cash flow / net income1.21x
Accruals ratio-1.6%
Payout ratio—
Capex / revenue7.2%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $1.39B | $1.25B |
| Cost of revenue | $448.18M | $399.95M |
| Gross profit | $939.87M | $853.48M |
| R&D expense | $185.76M | $182.51M |
| SG&A expense | $548.81M | $508.88M |
| Operating income | $199.39M | $129.05M |
| Interest expense | $49.29M | $63.07M |
| Pretax income | -$220.78M | $88.31M |
| Income tax | $21.64M | $25.06M |
| Net income | -$242.47M | $63.23M |
| EBITDA | $227.95M | $154.16M |
| EPS (basic) | -4.45 | 1.17 |
| EPS (diluted) | -4.45 | 1.16 |
| Weighted avg. shares (diluted) | 54.55M | 54.57M |
| Balance sheet | ||
| Cash & equivalents | $635.55M | $723.56M |
| Receivables | $215.99M | $193.16M |
| Inventory | $164.70M | $147.57M |
| Current assets | $1.10B | $1.13B |
| PP&E, net | $242.60M | $170.26M |
| Goodwill | $792.84M | $750.01M |
| Intangibles | $229.96M | $237.29M |
| Total assets | $2.61B | $2.51B |
| Current liabilities | $808.07M | $392.12M |
| Short-term debt | $31.47M | $78.00M |
| Long-term debt | $345.19M | $549.62M |
| Total debt | $376.66M | $627.63M |
| Total liabilities | $1.41B | $1.19B |
| Shareholders' equity | $1.20B | $1.32B |
| Net debt | -$258.89M | -$95.93M |
| Shares outstanding | 54.65M | 54.35M |
| Cash flow statement | ||
| Operating cash flow | $254.34M | $183.04M |
| Capital expenditure | $81.05M | $47.11M |
| Free cash flow | $173.29M | $135.93M |
| Investing cash flow | -$72.91M | -$48.16M |
| Financing cash flow | -$285.66M | $18.55M |
| Depreciation & amortization | $28.56M | $25.10M |
| Stock-based compensation | $36.29M | $33.93M |
Free plan shows the latest 2 periods; Pro shows all 13 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.